Does raising the pacing lower rate limit from 50 to 60 bpm affect LVEF and myocardial remodeling?

There is no dedicated evidence base that answers this question as posed. No randomized trial, and to date no registry analysis, has isolated a lower rate limit of 50 versus 60 bpm as an intervention and tracked ejection fraction and remodeling over five years in a device-exchange cohort. The honest answer is a mechanistic synthesis with explicit attention to why the available trial literature does not transfer cleanly, plus where a real effect could plausibly hide.

01Why the heart failure rate-lowering literature does not transfer

The first assumption worth dismantling is the implicit framing borrowed from the heart-failure-with-reduced-ejection-fraction rate-lowering literature. SHIFT (ivabradine, baseline sinus heart rate at least 70 bpm, ejection fraction 35% or below) and its remodeling substudy showed reductions in left ventricular end-systolic volume index tracking the achieved heart-rate reduction. That body of work concerns pathologically elevated, sympathetically driven resting tachycardia in failing myocardium, and the benefit is monotonic with how far heart rate is pulled down from the 75–85 bpm range.

Raising a programmed pacing floor from 50 to 60 bpm in a structurally preserved heart is not the thermodynamic inverse of that. The intervention is not re-creating the harm those trials reversed, because it operates two octaves away on the rate axis and in a different substrate. The epidemiologic observation that elevated resting heart rate is a risk marker is likewise observational, reflects intrinsic autonomic tone, and is heavily confounded; it says nothing about an externally imposed paced floor.

02Mechanistic decomposition of a 50→60 bpm floor change

At rest, the hemodynamic difference between 50 and 60 bpm is trivial. Cardiac output is defended by stroke-volume reserve, and the increment in mean wall stress, myocardial oxygen consumption, and tension-time index across a 10 bpm band at the low end of the curve is negligible. The force-frequency relationship is the relevant lens: positive in healthy myocardium, flat-to-inverted in advanced failure, but in either case the 50–60 segment sits on a nearly flat portion of the curve, so the inotropic consequence is essentially nil. Diastolic filling time shortens modestly at 60 bpm; this is clinically irrelevant in a compliant ventricle and theoretically double-edged in a stiff one, but not a remodeling driver at this magnitude.

03Burden, capture type, and why conduction system pacing changes the calculus

The remodeling penalty that defined the right-ventricular-apical era was a function of dyssynchronous activation, not of rate. With preserved physiologic left bundle branch area pacing (LBBAP) capture — narrow paced QRS, maintained interventricular and intraventricular synchrony — the incremental ventricular pacing induced by a higher floor carries little of that penalty. In a structurally preserved LBBAP system, the expected five-year trajectory of ejection fraction and chamber volumes is dominated by capture type, total pacing burden, and underlying substrate, with the 10 bpm floor itself contributing no measurable independent effect in either direction.

The 2025 ESC/EHRA Clinical Consensus Statement on conduction system pacing anchors benefit to burden, recommending conduction system pacing for patients with an expected ventricular pacing burden above 20% and mildly reduced ejection fraction, and frames the remodeling penalty of conventional right ventricular pacing as a consequence of non-physiologic activation, with pacing-induced cardiomyopathy reported in roughly 15–20% of chronically paced patients. Contemporary meta-analyses confirm LBBAP is superior to right ventricular pacing in reducing QRS duration and left ventricular end-diastolic diameter and in preserving ejection fraction in atrioventricular block with preserved function.

04What the 2023–2025 randomized and registry data show

The single most relevant trial is DANPACE II, a nationwide randomized controlled trial of 540 sinus-node-dysfunction patients assigned to a base rate of 60 bpm with rate-adaptive pacing versus 40 bpm without it. It is the closest approximation to the intervention in question, shifted one band lower. Two findings matter. First, atrial pacing minimization did not reduce the incidence of atrial fibrillation. Second, and more pointed, the lower-rate arm had significantly more syncope or presyncope, and most crossovers from the lower-rate arm were driven by chronotropic incompetence. The best randomized evidence in the low-rate band therefore shows that going lower buys nothing on the arrhythmia side and costs on the hemodynamic and chronotropic side. There is no symmetric signal that a higher floor is harmful.

The one dataset pulling the other way is a large cardiac resynchronization defibrillator registry in which a lower programmed rate limit was associated with improved survival, with the lowest setting carrying the largest apparent benefit. That analysis is observational and confounded: a low rate limit marked younger patients with less atrial fibrillation and a lower heart rate score, that is, a healthier and more autonomically intact population that can be left to its own intrinsic rhythm. It is also a heart-failure population, not preserved-function bradycardia pacing, so it does not transfer to this substrate.

05Where the floor could actually matter

The clinically real effects split into two opposite edge cases. On one side, in the presence of chronotropic incompetence or symptomatic relative bradycardia, a 60 bpm floor is plausibly beneficial — consistent with the DANPACE II crossover pattern. On the other side, in a patient with a low intrinsic resting rate, a 60 bpm floor paces unnecessarily through that resting bradycardia, raises atrial-paced percentage and battery drain, abolishes the low-rate phenotype, and can blunt nocturnal heart-rate dipping and autonomic surveillance metrics. None of that is a remodeling signal; it is the genuine physiologic and metrologic cost, and it is precisely the consideration absent from the heart-failure rate literature.

06Measurement resolution and individualized monitoring

A 10 bpm floor change sits below the detection floor of ejection fraction measurement. Test-retest variability of echocardiographic ejection fraction is on the order of 5–8% absolute, so a true effect of this magnitude, if it existed, would be unrecoverable from serial ejection fraction. The only instruments with the resolution to detect anything would be global longitudinal strain (test-retest roughly 1–2% absolute) and indexed volumetrics trended over years, paired with the pacing-percentage trend and the autonomic metrics. Even then, the predicted result is a null for remodeling and a measurable shift only in pacing-burden and autonomic-tone variables.

07Bottom line

The literature contains no five-year ejection fraction or remodeling readout for a 50-to-60 bpm floor change, and the mechanistic prediction is a null for remodeling in a physiologic-capture system. What the recent evidence adds is randomized reassurance that the higher floor is not the harmful direction in this band — DANPACE II makes the lower floor the one with a demonstrated downside — and confirmation that any real cost of a 60 bpm floor in a low-intrinsic-rate phenotype is autonomic, metrologic, and battery-related rather than structural. For longitudinal monitoring, the informative endpoints are atrial-paced percentage, heart rate score, nocturnal dipping, and heart-rate-variability metrics, not ejection fraction or volumetrics.